Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-01-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于收到药物临床试验批件及审批意见通知件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company regarding the receipt of clinical trial approval documents and regulatory opinions from the National Medical Products Administration (国家食品药品监督管理总局). It details the approval status of certain drugs and the company's plans for subsequent regulatory filings and clinical trials. The document is short (998 characters) and serves as an official notification to investors about regulatory developments and potential impacts on the company, rather than a detailed financial report or presentation. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2016-01-27 Chinese
2015年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2015 annual performance forecast (业绩预告) from 福安药业 (Fuan Pharmaceutical). It provides estimated net profit figures for the full year 2015 and explains reasons for performance changes. It explicitly states that the forecast has not been audited and that detailed data will be disclosed in the 2015 annual report. The document is short (857 characters) and serves as a preliminary earnings forecast rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not the full annual report (10-K). FY 2015
2016-01-26 Chinese
关于撤回部分药品注册申请的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 福安药业（集团）股份有限公司 regarding the withdrawal of certain drug registration applications. It references regulatory guidance from the 国家食品药品监督管理总局 (National Medical Products Administration) and explains the reasons and impact of the withdrawal. The document is short (1073 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is not an annual report, interim report, earnings release, or any detailed financial or management report. Instead, it is a regulatory announcement about a specific corporate action related to drug registration applications. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-01-21 Chinese
关于收到药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of drug clinical trial approval certificates from the National Medical Products Administration. It contains no financial data, no report or presentation, and no mention of shareholder votes or management changes. It is a regulatory announcement about clinical trial approvals, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. The document is short (799 characters) and is an official disclosure of regulatory approval information. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2016-01-21 Chinese
关于收到《中国证监会行政许可申请受理通知书》的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (524 characters) from a company about receiving an administrative license acceptance notice from the China Securities Regulatory Commission regarding an application for approval of an asset purchase by issuing shares. It states the application has been accepted for review but approval is uncertain. The document does not contain financial statements or detailed financial data, nor is it a full report. It is an announcement about a regulatory process related to a capital transaction (asset purchase via share issuance). Given the content and length, it fits best as a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not merely a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2016-01-15 Chinese
关于公司收到药品再注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving drug re-registration approvals from a regulatory authority (Chongqing Food and Drug Administration). It contains no financial data, no mention of financial results, no management discussion, no voting results, no capital changes, no legal proceedings, and no detailed report content. The document is an official regulatory announcement about product registration status, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a regulatory announcement about compliance and approvals, best classified under Regulatory Filings (RNS). The document length is short (694 characters), and it is not a report publication announcement or certification letter, but a regulatory announcement. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2016-01-12 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.